Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of
acute venous thromboembolism. This study sought to evaluate the efficacy and safety of …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Currently available anticoagulants include heparin, low-molecular-weight heparin,
fondaparinux and warfarin. Despite advances, currently available agents have limitations …

Abstract Abstract LBA-1 Background: Apixaban, an oral factor Xa inhibitor, may provide a
simple, fixed-dose regimen for extended treatment of venous thromboembolism. Objectives …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐
Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to …